Korean J Helicobacter Up Gastrointest Res.  2019 Dec;19(4):225-230. 10.7704/kjhugr.2019.0019.

Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance

Affiliations
  • 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. jwchulkr@catholic.ac.kr

Abstract

Addressing the increasing antibiotic resistance, including clarithromycin resistance, which affects Helicobacter pylori (H. pylori) eradication therapy, is a challenge for clinicians. Antibiotic resistance is the main reason for H. pylori eradication failure and the resistance rate for clarithromycin may drastically increase, up to 38.5%, due to 23S ribosomal RNA point mutations. Therefore, the standard triple regimen is no longer suitable as the first-line treatment in most regions. However, there is a growing interest in personalized care for patients. Increased eradication rates of tailored therapy based on antibiotic susceptibility have been reported using nucleic acid-based techniques for clarithromycin resistance with a focus on the first-line eradication therapy of H. pylori infection. Herein, we discuss the eradication therapy for H. pylori, with a diagnostic test and appropriate treatment for clarithromycin resistance.

Keyword

Clarithromycin; Drug resistance; Eradication; Helicobacter pylori

MeSH Terms

Clarithromycin*
Diagnostic Tests, Routine*
Drug Resistance
Drug Resistance, Microbial
Helicobacter pylori*
Helicobacter*
Humans
Point Mutation
RNA, Ribosomal, 23S
Clarithromycin
RNA, Ribosomal, 23S
Full Text Links
  • KJHUGR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error